Welcome!

News Feed Item

Treatment for Facial Redness Associated With Rosacea Now Available in the UK

LONDON, April 17, 2014 /PRNewswire/ --

Mirvaso® (brimonidine) 3 mg/g gel an alpha-2 adrenergic agonist indicated for the symptomatic treatment of the redness (facial erythema) associated with rosacea in adult patients, is now available in the UK.

     (Photo: http://photos.prnewswire.com/prnh/20140416/680993-INFO )

The active ingredient, brimonidine, restricts excessive blood flow to the upper layers of the skin. The topical gel is applied to the forehead, chin, nose and cheeks, and can reduce facial redness for up to 12 hours[1]. Mirvaso offers a new and effective management option for a commonly misunderstood inflammatory skin condition.

Dr Anton Alexandroff, Consultant Dermatologist at University Hospitals Leicester, said: "Rosacea is often misunderstood and until now we have been extremely limited in the options we can offer people suffering from facial redness. Typically the symptoms associated with rosacea get worse if left untreated so it's key that we recognise and treat this condition."

Rosacea is a progressive, long-term condition that affects over 10% of adults in the UK[2]. It is characterised by facial redness and flushing called erythema[3], caused by abnormal blood flow to the skin's top layers. It can lead to bumps and pimples (papules and pustules)[3] and, in severe cases, facial disfiguration, if left unmanaged.

Dr Ellie Cannon, General Practitioner, added: "Many people underestimate the impact of the flushing and redness associated with rosacea: if it is not appropriately managed it can severely impact a person's life, causing anxiety, embarrassment, low self-esteem and isolation. It is often discounted simply as blushing but the sad truth is that people are judged negatively as a result of this very visible condition."

Rosacea's exact cause is unknown but chronic inflammation is believed to play a key role. Certain triggers: heat, cold, intense physical exercise, alcohol and caffeine[4], can intensify it. Until now, rosacea management was limited to dietary and lifestyle adjustments like avoiding key triggers. Some patients are prescribed anti-inflammatory antibiotics - which treat the pimples and pustules associated with rosacea but fail to combat facial redness and flushing[4].

To access the SPC, please visit: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002642/WC500163121.pdf

For further information about the disease, please visit: http://www.myrosacea.co.uk

For further information about the company, please visit: http://www.galderma.co.uk

Galderma - a global company exclusively dedicated to dermatology

Galderma is a global company founded in 1981 committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals around the world.  The company has 33 wholly-owned affiliates with a worldwide network of distributors and more than 5,000 employees. Galderma's extensive product portfolio is available in 80 countries and treats a range of dermatological conditions including: acne, rosacea, onychomycosis, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical solutions for skin senescence.

With approximately 19% of revenues invested each year to discover and develop new products and access innovative technologies, the company is one of the world's leading investors in dermatology R&D. Five state-of-the-art R&D centers and five manufacturing sites are dedicated to providing a wide range of innovative medical solutions which meet the highest standards of safety and efficacy.

Strategic brands include Epiduo, Efracea, Etrivex, Differin, Mirvaso®, Rozex/MetroGel, Silkis, Loceryl/Curanail, Cetaphil, Metvix, Azzalure, Restylane and Emervel.

References  

1. J Fowler, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, vehicle- controlled pivotal studies. J Drugs Dermatol 2013;12(6): 650-656.

2. NHS Choices. Rosacea Introduction. http://www.nhs.uk/conditions/Rosacea/Pages/Introduction.aspx  Last accessed March 2014.

3. Powell FC. Rosacea. N Engl J Med. 2005;352:793-80.

4. NICE guidelines. Rosacea.  http://cks.nice.org.uk/rosacea#!topicsummary Last accessed March 2014.

MRV/059/0414
Date of Preparation: April 2014

Contacts: 

Galderma (UK) Ltd
Ruth Baxter
Group Product Manager
Tel: +44(0)1923-208950
E-mail: [email protected]

Ruder Finn
Donna Wright
Account Director
Tel: +44(0)20-7438-3085
E-mail: [email protected]


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Hitachi, the leading provider the Internet of Things and Digital Transformation, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Hitachi Data Systems, a wholly owned subsidiary of Hitachi, Ltd., offers an integrated portfolio of services and solutions that enable digital transformation through enhanced data management, governance, mobility and analytics. We help globa...
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
In his session at 20th Cloud Expo, Scott Davis, CTO of Embotics, will discuss how automation can provide the dynamic management required to cost-effectively deliver microservices and container solutions at scale. He will discuss how flexible automation is the key to effectively bridging and seamlessly coordinating both IT and developer needs for component orchestration across disparate clouds – an increasingly important requirement at today’s multi-cloud enterprise.
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in compute, storage and networking technologies, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/...
Everyone wants to use containers, but monitoring containers is hard. New ephemeral architecture introduces new challenges in how monitoring tools need to monitor and visualize containers, so your team can make sense of everything. In his session at @DevOpsSummit, David Gildeh, co-founder and CEO of Outlyer, will go through the challenges and show there is light at the end of the tunnel if you use the right tools and understand what you need to be monitoring to successfully use containers in your...
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.
SYS-CON Events announced today that DatacenterDynamics has been named “Media Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY. DatacenterDynamics is a brand of DCD Group, a global B2B media and publishing company that develops products to help senior professionals in the world's most ICT dependent organizations make risk-based infrastructure and capacity decisions.
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
NHK, Japan Broadcasting, will feature the upcoming @ThingsExpo Silicon Valley in a special 'Internet of Things' and smart technology documentary that will be filmed on the expo floor between November 3 to 5, 2015, in Santa Clara. NHK is the sole public TV network in Japan equivalent to the BBC in the UK and the largest in Asia with many award-winning science and technology programs. Japanese TV is producing a documentary about IoT and Smart technology and will be covering @ThingsExpo Silicon Val...
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor – all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
Building a cross-cloud operational model can be a daunting task. Per-cloud silos are not the answer, but neither is a fully generic abstraction plane that strips out capabilities unique to a particular provider. In his session at 20th Cloud Expo, Chris Wolf, VP & Chief Technology Officer, Global Field & Industry at VMware, will discuss how successful organizations approach cloud operations and management, with insights into where operations should be centralized and when it’s best to decentraliz...
“DevOps is really about the business. The business is under pressure today, competitively in the marketplace to respond to the expectations of the customer. The business is driving IT and the problem is that IT isn't responding fast enough," explained Mark Levy, Senior Product Marketing Manager at Serena Software, in this SYS-CON.tv interview at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
@DevOpsSummit at Cloud taking place June 6-8, 2017, at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long developm...